Background
==========

The question of when antiretroviral therapy has to be initiated remains a challenging issue. Recent studies show that the early immune response to HIV-1 infection is likely to be an important factor in determining the clinical course of disease \[[@B1]\]. The first weeks following HIV-1 transmission are extremely dynamic. They are associated with rapid damage to generative immune cell micro-environments and with immune responses that partially control the virus. Following HIV-1 infection, the virus first replicates locally in the mucosa and then is transported to draining lymph nodes where further amplification occurs. This initial phase of infection, until the systemic viral dissemination begins, constitutes the eclipse phase \[[@B1]\]. In general, there is an exponential increase in plasma viremia with a peak 21-28 days after infection. By this time, significant depletion of mucosal CD4^+^T cells has already occurred. Around the time of peak viremia, patients may become symptomatic and reservoirs of latent virus are established \[[@B1],[@B2]\].

The \"window of opportunity\" between the infection and peaking of viremia, prior to massive CD4^+^T cell destruction and the establishment of viral reservoirs, seems to be a narrow but crucial period in which an antiretroviral therapy can control viral replication, prevent an extensive CD4^+^T cell depletion from occurring and curb generalized immune activation. Thus, thwarting HIV replication by introducing HAART in the early phases of infection could have a substantial impact on the whole disease course. In particular, suggested factors that may contribute to the observed better viral control after treatment interruption in very early treated patients are \[[@B3]\]: *i*) early arrest of viral escape, leaving the virus vulnerable; *ii*) preservation or even enhancement of the immune response resulting from the early clearing of antigen; *iii*) prevention of the establishment of a pool of HIV-specific memory CD4 T cells thus leaving fewer target cells available for viral infection.

An ideal clinical model aimed at addressing such issue should compare a number of patients treated starting on different times: from very early to very late. Besides the ethical issues, it is rather difficult to collect enough patients to significantly represent the whole spectrum of possible HAART initiation timings. As a matter of fact, a practical clinical model would compare very early to late-treated patients. While informative on the overall role of HAART timing on disease course, this approach would not allow to verify if there are events in the early infection influenced by the starting time of HAART that affect directly and decisively the course of the disease.

We have already shown in \[[@B4]-[@B6]\] that an agent-based model of HIV-1 infection could be a valuable tool for the study of the AIDS disease progression and treatment. The computerized simulation allows us to track the effect of HAART timing on the progression of the disease.

The aim of the present work is to verify the effect of HAART timing on subsequent events. Indeed, both a clinical model and a computational simulation show that a late initiation of treatment affects HIV-1 replication control. Interestingly, the *in silico*model identifies a significant three-week time threshold as the \"ultimate\" time point beyond which the decisive HIV-induced damages already occurred, affecting the whole disease course.

In a previous work \[[@B4]\], we analyzed clinical data of patients initiating HAART within six months from infection (i.e., we called that *early*phase) and performed computer simulations to predict the differences in viral rebound at therapy interruption between those patients and subjects initiating therapy during the chronic phase (i.e., we called that *late*phase, corresponding to initiating six or more months after infection). Our conclusion was that early initiation of therapy does not prolong the disease-free period when compared to a treatment started during the late phase. However, other studies suggest that an earlier initiation is preferable \[[@B7]-[@B9]\]. This motivated us to better identify the meaning of early initiation. In the present article, we extend the analysis in \[[@B4]\] to get a more complete picture. We analyze clinical data of *very early*patients (i.e., treated before seroconvertion) against late-treated patients.

Methods
=======

Clinical studies
----------------

We analyzed the results of clinical studies performed at the Clinical Department of the National Institute for Infectious Disease \"L. Spallanzani\" in Rome.

A first group of eleven patients (9 male and 2 female) were diagnosed HIV-1 positive between year 1998 and 2006. All patients initiated HAART within 14 days from diagnosis, during the very early phase of infection (see Table [1](#T1){ref-type="table"}). The very early phase was defined as having a negative or indeterminate western blot for HIV-1 antibodies in combination with a positive test for either p24 antigen or a detectable HIV-1 RNA concentration. Those patients were treated with zidovudine/lamivudine (CBV) in combination with either the reverse transcriptase inhibitor efavirenz (EFZ) or one protease inhibitor lopinavir/ritonavir (KAL) or indinavir (IDV). Because anaemia and neutropenia were diagnosed, in two cases CBV has been substituted with lamivudine (3TC) and staduvine (D4T). All those patients underwent a therapy cycle for 2 ± 1 years and remained off HAART for about 48 weeks.

###### 

Very early subjects with an immediate treatment before seroconversion.

  ID      Therapy^†^therapy   Elapsed days ^‡^therapy   At diagnosis\*   4 weeks after\*\*   8 weeks after\*\*                  
  ------- ------------------- ------------------------- ---------------- ------------------- ------------------- ------- ------ -------
  Pz4     CBV, IDV            14                        603              16000               800                 \< 50   792    6000
  Pz34    CBV, EFZ            18                        370              280000              647                 640     815    \< 50
  Pz36    CBV, EFZ            15                        402              14000                                   \< 50   599    \< 50
  Pz38    CBV, EFZ            2                         543              3500000                                 1600    770    220
  Pz41    CBV, EFZ            12                        568              1300000             1549                \< 50   857    \< 50
  Pz42    CBV, EFZ            8                         234                                  1083                2300    657    \< 50
  Pz47    CBV, IDV            4                         753              8802                615                 220     743    \< 50
  Pz51    CBV, EFZ            10                        530              91972               655                 \< 50   810    \< 50
  Pz67    CBV, KAL            0                         797              21675               884                 98      932    \< 50
  Pz83    CBV, KAL            18                        426              \> 500000           770                 2349    1524   1037
  Pz113   CBV, KAL            3                         261              65716               422                 660     460    302

Clinical information about the eleven patients selected at the Clinical Department of the National Institute for Infectious Disease \"L. Spallanzani\" in Rome. All subjects received HAART within six months from primary infection.

^†^CBV, Combivir (AZT Zidovudine plus 3TC Lamivudine); IDV, Indinavir; EFZ, Efavirenz; KAL, Kaletra (lopinavir/ritonavir). ^‡^Days elapsed from diagnosis (enrollment) to initiation of HAART. \*CD4 and CD8 are per microlitre of plasma, viremia is per millilitre of plasma. \*\* 4 weeks after treatment interruption.

The second group is made up by twenty-two patients (21 male and 1 female) enrolled in the program between year 1998 and 2005. Patients in this group underwent HAART during the early phase of HIV-1 infection. In particular, they started HAART about 20 days after treatment diagnosis (see Table [2](#T2){ref-type="table"}). Early patients were defined as having documented seronegative HIV-1 antibody test within the previous 6 months; acute symptomatic seroconversion illness; evolving HIV-specific antibody response by ELISA; positive HIV-DNA PCR in PBMC. Those patients were treated with three different drugs (in the majority of cases zidovudine (AZT) plus 3TC plus a protease inhibitor. Further details can be found in Table One of \[[@B4]\]. All those patients underwent a therapy cycle for 3 ± 1 years and remained o HAART for about 88 weeks.

###### 

Early subjects with an immediate treatment of acute HIV-1 infection.

  ID      Therapy^†^        Elapsed days ^‡^   Days on therapy   Days out therapy   At diagnosis\*   At first interruption                        
  ------- ----------------- ------------------ ----------------- ------------------ ---------------- ----------------------- ------ ------ ------ -------
  Pt 03   D4T,3TC,IDV       14                 1775              27                 653              1659                    75     809    459    5794
  Pt 05   AZT,3TC,IDV       61                 1657              27                 444              633                     100    867    476    \< 50
  Pt 29   AZT,3TC,NFV       14                 1069              28                 1103             1964                    31     741    844    \< 50
  Pt 33   AZT,3TC,IDV       66                 925               28                 424              991                     0.13   458    474    147
  Pt 35   AZT,3TC,EFV       1                  1041              30                 522              1205                    78     919    607    496
  Pt 37   AZT,3TC,EFV       0                  1371              790                545              1233                    3.9    901    384    \< 50
  Pt 58   AZT,3TC,EFV       3                  442               27                 768              1632                    50     1451   1580   \< 50
  Pt 06   AZT,3TC,IDV       32                 1620              1908               882              4146                    4.1    754    726    \< 50
  Pt 18   AZT,3TC,IDV       26                 635               213                1319             1810                    15     1718   825    \< 80
  Pt 24   AZT,3TC,IDV       3                  1231              542                507              3162                    78     513    1067   \< 50
  Pt 31   AZT,3TC,EFV       19                 1102              1654               322              243                     490    1154   1165   \< 50
  Pt 41   AZT,3TC,EFV       12                 705               1837               568              278                     130    1326   940    \< 50
  Pt 45   AZT,3TC,EFV       5                  488               55                 307              1032                    130    872    506    \< 50
  Pt 53   AZT,3TC,Lop/rit   16                 503               179                341              779                     18.9   545    529    150
  Pt 04   AZT,3TC,IDV       6                  1561              2155               603              1288                    1.6    1047   1015   88
  Pt 19   AZT,3TC,IDV       13                 1480              1640               1338             716                     10     1113   447    \< 50
  Pt 28   AZT,3TC,NFV       7                  325               70                 281              860                     190    863    485    \< 80
  Pt 32   AZT,3TC,EFV       15                 1384              669                409              1448                    4.3    960    331    \< 50
  Pt 72   AZT,3TC,LPV       7                  318               343                827              386                     19     1005   751    \< 50
  Pt 81   AZT,3TC,NVP       33                 745               317                412              264                     32.5   522    461    68
  Pt 85   AZT,3TC,Lop/rit   46                 717               717                326              669                     50     855    1436   \< 50
  Pt 92   3TC,Lop/rit,TNF   0                  455               331                616              3774                    46.3   1027   913    \< 50

Clinical information about the twenty-two patients selected at the Clinical Department of the National Institute for Infectious Disease \"L. Spallanzani\" in Rome. All subjects received HAART within six months from primary infection.

^†^D4T, staduvine; 3TC, lamivudine; IDV, Indinavir; AZT, Zidovudine; NFV, nelflnavir; EFV, Efavirenz; NVP, nevirapine; TNF, Tenofovir; Lop, lopinavir; Rit, Ritonavir; LPV (KAL), Kaletra (lopinavir/ritonavir). ^‡^Days elapsed from diagnosis (enrollment) to initiation of HAART. \*CD4 and CD8 are per microlitre of plasma, viremia is per millilitre of plasma.

The third group consists of twenty-one patients (12 male, 9 female). They started HAART during the chronic phase of infection defined as suggested by the guidelines \[[@B10]\]. In particular, they started HAART about 3.5 years after treatment diagnosis (see Table [3](#T3){ref-type="table"}). Their CD4 count at initiation was 400 ± 150 per microlitre of plasma. The range of calendar year for starting HAART among those patients was 1998 ± 3. All those patients underwent a therapy cycle for 4 ± 2 years and remained off HAART for about 41 weeks. The Ethical Committee of the \"L. Spallanzani\" Institute approved the study and the patients gave a written informed consent.

###### 

Late subjects with deferred treatment of acute HIV-1 infection.

  ID      Therapy^†^        Elapsed days ^‡^   Days on therapy   Days out therapy   At diagnosis\*   At first interruption                          
  ------- ----------------- ------------------ ----------------- ------------------ ---------------- ----------------------- -------- ------ ------ -------
  Pt 07   AZT, 3TC          300                1303              606                463              2498                    34000    614    3101   9154
  Pt 12   D4T, 3TC, SQV     26                 1117              89                 422              754                     62000    601    948    \< 50
  Pt 16   AZT, ddC, Rit     9                  1803              66                 116              1170                    990000   483    1165   \< 50
  Pt 17   AZT, 3TC          49                 1872              412                51               1155                    110000   693    1359   150
  Pt 18   AZT, ddl          268                1615              558                340              994                     35000    989    1172   \< 50
  Pt 19   AZT, 3TC          393                819               206                559              1230                    70319    616    825    \< 50
  Pt 20   AZT, 3TC          15                 2503              21                 235              877                     230000   566    1246   \< 50
  Pt 22   D4T, 3TC          0                  1807              64                 290                                      140000   1334          \< 50
  Pt 23   AZT, 3TC          483                2109              248                409              734                     47000    686    572    \< 50
  Pt 25   D4T,3TC, IDV      22                 1661              625                383              809                     37000    896    1208   \< 50
  Pt 26   AZT, 3TC          38                 841               1150               540              1256                    16000    719    640    \< 50
  Pt 27   AZT,3TC           10                 1885              50                 332                                      2800     636           \< 50
  Pt 28   AZT,3TC,EFV       0                  3131              373                556                                      1900     752           \< 50
  Pt 29   AZT,3TC,Lop/rit   21                 1950              69                 483                                      150000   1233          100
  Pt 31   AZT,3TC,IDV       0                  1255              109                574              1625                    7900     813    640    \< 50
  Pt 32   AZT,3TC,IDV       0                  1472              160                393                                      1335     1235          \< 50
  Pt 33   D4T, 3TC          407                523               66                 479              494                     473      705    450    \< 50
  Pt 34   ddl, D4T, NVP     13                 2207              54                 493              1628                    230000   907    943    \< 50
  Pt 38   AZT,3TC,LPV       0                  1460              270                481              1156                    20000    534    964    \< 50
  Pt 39   AZT,3TC,NVP       64                 2734              767                539                                      41000    859           \< 50
  Pt 41   AZT,3TC,Lop/rit   62                 428               89                 200                                      135000   848           \< 50

Clinical information about the twenty-one patients selected at the Clinical Department of the National Institute for Infectious Disease \"L. Spallanzani\" in Rome. All subjects received HAART during chronic phase of infection.

^†^AZT, Retrovir (Zidovudine); 3TC, Epivir (Lamivudine); D4T, Zerit (Staduvine); SQV, Saquinvir (Invirase); Zalcitabina (ddC, Hivid); Rit, Ritonavir (Norvir); ddl, Didanosine (Videx); IDV, Indinavir (Crix-ivan); EFV, Efavirenz; NVP, Nevirapine (Viramune); LPV (Lop), Lopinavir; ^‡^Days elapsed from diagnosis (enrollment) to initiation of HAART. \*CD4 and CD8 are per microlitre of plasma, viremia is per millilitre of plasma.

Plasma HIV-1 determination
--------------------------

Plasma HIV-1 RNA levels were determined by a second-generation assay based on nucleic acid sequence based amplification (NASBA), for samples collected until 2001 and by the branched-chain DNA assay (Versant HIV RNA test, Version 3.0, lower limit of quantification 50 copies/*ml*; Bayer Diagnostics, Milan, Italy) from 2001 until 2008.

Computational model
-------------------

The current version of the model we employ derives from an early simulator that has been quite extensively described in previous publications \[[@B11],[@B12]\]. Recently it has been specialized to simulate the HIV-1 infection \[[@B6]\] and the effects of antiretroviral therapy \[[@B4]\].

Briefly, it resorts to bit strings to represent \"binding sites\" of cells and molecules, as for example lymphocyte receptors, MHC, antigen peptides and epitopes, immunocomplexes, etc. \[[@B13]\]. The model includes the major classes of cells of the lymphoid lineage (T helper lymphocytes, cytotoxic T lymphocytes, B lymphocytes and antibody-producer plasma cells) and some of the myeloid lineage (macrophages and dendritic cells). These entities are individually represented. In contrast to cells, cytokines like interleukin-2 are represented in terms of concentrations and their dynamics described by a parabolic partial differential equation plus a degradation term accounting for the finite half-life \[[@B5],[@B14]\]. Modeling features of the HIV infection include HIV replication inside infected lymphocytes, T production impairment; specific response against HIV strains and HIV mutation.

The simulated life cycle of the virus is represented by the following stages: 1) the virus infects CD4^+^T cells, macrophages, dendritic cells; 2) reverse transcriptase copies the viral single stranded RNA genome into a double-stranded viral DNA. The viral DNA is then integrated into the host chromosomal DNA; 3) the virus remains at rest until an event activates the transcription; 4) the replicating virus buds from the cell membrane. Fully assembled virions are then able to infect other cells to restart the life cycle. HAAR effects are modeled as follows: Reverse transcriptase inhibitors block reverse transcriptase enzymatic functions and avoid completion of synthesis of the double-stranded viral DNA thus preventing HIV-1 from replicating (i.e., it prevents the virus in stage 1 from reaching stage 2); Protease inhibitors prevent viral replication by inhibiting the activity of HIV-1 protease, an enzyme used by the virus to cleave nascent proteins for final assembly of new virions (i.e., it prevents virus assembly in stage 4). Further details and parameter settings of the simulations can be found in the Additional file [1](#S1){ref-type="supplementary-material"}.

For what concerns the setting of the parameters related to the therapy, we performed computer simulations in which we fixed the immunological parameters at the time of therapy initiation on the basis of the average values measured in patients *in vivo*: 5.8 ± 0.2 RNA copies/*ml*(in logarithmic scale), 870 ± 50 CD4 cells/*μl*and 430 ± 50 CD8 cells/*μl*. For all simulations we applied a one-year course of HAART. Further details on the tuning of the simulation parameters can be found in the Additional file [2](#S2){ref-type="supplementary-material"}.

Results
=======

We analyze virological data from HIV patients treated during the very early, early and late phase of infection and compare them with computer simulations.

In Figure [1](#F1){ref-type="fig"} clinical data of all three analyzed groups is shown altogether. In a point-by-point comparison we find no statistical difference in viral rebound between early and late-treated patients (P ≥ 0.05, Mann-Whitney U two-tailed test) confirming the results of \[[@B4]\]. In addition, we observe that a difference does exist for very early initiation of therapy (P \< 0.05, Mann-Whitney U two-tailed test).

![**Plasma HIV-1 RNA load**. The mean plasma HIV-1 RNA load versus time in weeks after interruption of HAART for patients classified in late (21 subjects), early (22 subjects) and very early (11 subjects) groups. Error bars show standard deviations. The features of the three clinical settings are given in section Patients and Methods.](1471-2334-11-56-1){#F1}

In the present work we extend the simulations of \[[@B4]\] to include the new clinical settings corresponding to a very early initiation of therapy. In particular, the very early simulation settings correspond to a beginning of the therapy within the first week whereas the late settings correspond to initiating therapy between week five and six from infection.

Figure [2](#F2){ref-type="fig"} summarizes data of virological rebound (averages) after therapy interruption at different time points (4, 8 and 24 weeks) for very early and late patients for both clinical (empty boxes) and simulation data (filled boxes). Firstly, the figure shows that clinical and simulation data are in good agreement (differences are not statistically significant: P ≥ 0.05, Mann-Whitney U two-tailed test). Secondly, the difference in plasma HIV-1 RNA (copies/ml) between very early and late-treated patients decreases with increasing time from therapy interruption. Panel (a) shows a difference of about two logs with panel (b) for both clinical data and simulations. These differences vanish after 24 weeks from therapy interruption (cfr. panel (e) and (f)). The overall message is that a delay in the initiation of therapy reduces the chances of maintaining a therapy effect at discontinuation.

![**Virological rebound**. Virological rebound after 4 weeks (top), 8 weeks (middle) and 24 weeks (bottom) from therapy interruption for two groups: very early (green boxes) that started HAART before seroconversion and late (blue boxes) that started HAART during chronic phase of primary HIV-1 infection. Filled boxes represent *in silico*data (resulting from three thousands runs) whereas empty boxes correspond to *in vivo*data. We have calculated the Mann-Whitney U test statistics for assessing whether the two independent samples (*in silico and in vivo*) come from the same distribution. In all cases we did not find a significant difference (P ≥ 0.05, Mann-Whitney U two-tailed test). Black lines indicate standard deviations. Information on parameter settings for the simulations can be found in the Additional file [1](#S1){ref-type="supplementary-material"}.](1471-2334-11-56-2){#F2}

In order to provide a more precise estimate of the time \"limit\" beyond which the benefit of an early initiation of therapy vanishes, we use the simulation to investigate the influence of HAART initiation time (*t~s~*) on the viral rebound. The corresponding results are shown in Figure [3](#F3){ref-type="fig"}. The virological rebound at *one week*after therapy interruption as a function of *t~s~*is presented. We observe that there are two regimens, one for *t~s~*\< 20 days and one for *t~s~*\> 30 corresponding to what clinicians call respectively *best controllers*(with undetectable HIV RNA levels) and *rebounders*(whose HIV viremia load returns, approximately, to the pre-HAART level).

![**Virological rebound after 1 weeks**. Virological rebound at 1 week after therapy interruption for different starting time points of HAART (*t~s~*). The red dots represent the results of thousands simulations and the fitting line is given by the Richards\' curve in equation 1. Standard deviation is about 0.1 log~10~(*copies/ml*) for all points. Inset plot is a zoom for *t~s~*\< 30 days. Parameters of the fitting curve are: *a*= 1.52, *k*= 3.79, *d*= 0.12, and $t_{s}^{*}$ = 23.50.](1471-2334-11-56-3){#F3}

The points in Figure [3](#F3){ref-type="fig"} fit pretty well a generalized logistic function (i.e., the Richards\' curve, \[[@B15]\]) describing the growth of viremia as a function of *t~s~*,

$$V(t_{s}) = a + \frac{k - a}{1 + e^{- d(t_{s} - t_{s}^{*})}}$$

where the parameter *k*is the carrying capacity or the upper asymptote, *a*is the lower asymptote, *d*is the growth rate, and $t_{s}^{*}$ is the time of maximum growth. By moving the time of the measurements beyond one week after therapy interruption, the resulting data still fit the same *V*(*t~s~*) but with a greater *a*, a smaller d and a greater $t_{s}^{*}$. In particular the limit for d going to zero, of *V*(*t~s~*) is (*a*+ *k*)/2 may lead to the deceiving conclusion that there is no window of opportunity because the viral rebound is independent from *t~s~*.

With respect to $t_{s}^{*}$, the value of\~ 23:5 days points to the early inflammation as a critical phase of the disease. To bring into focus this facet, we compare two simulated \"markers\" of the inflammation state in untreated (control case), very early and lately treated simulated patients (see Figure [4](#F4){ref-type="fig"}). These virtual markers are given by the cell counts of active macrophages (a) and dendritic cells presenting viral proteins on class II MHC molecules (b). We observe that the late-treated case is comparable to the control case (untreated) whereas the very early stands on its own. This observation suggests that it is the activation of the immune system through the set up of an in ammatory state that has to be blamed for the increased viral rebound for *t~s~*\>$t_{s}^{*}$.

![**Inflammatory response**. Cell counts of active macrophages (a) and dendritic cells presenting viral proteins on class II MHC molecules (b) show that, in the simulation, the late-treated case is comparable to the control case (untreated) whereas the very early case stands on its own. This suggests that the set up of an infiammatory state affects the viral rebound at therapy discontinuation. Counts are taken at week 8 for all groups. Therapy for very early started within the first week and for the late started at about week 6.](1471-2334-11-56-4){#F4}

Figure [4](#F4){ref-type="fig"} shows with clarity that very early initiation of the treatment can down-regulate the immune activation, hence limiting viral replication and spread. Interestingly, this view is supported by the observation that HIV triggers the immune activation directly (e.g., HIV gene products can induce the activation of lymphocytes and macrophages as well as the production of pro-inflammatory cytokines and chemokines \[[@B2]\]) or indirectly (e.g., sustained antigen-mediated immune activation occurs in HIV-1-infected patients due also to other viruses like the cytomegalovirus or the Epstein-Barr virus \[[@B2]\]). In both case, the result is a high level of pro-inflammatory cytokines, such as tumor necrosis factor alpha, interleukin 6 and interleukin 1 beta, right from the early stages of HIV-1 infection \[[@B2]\].

Discussion
==========

Recent analysis (performed by Fiebig et al. \[[@B16]\]) of samples from individuals that have been infected by HIV-1 has revealed that patients can be categorized into six stages on the basis of a sequential gain in positive HIV-1 clinical diagnostic assays (viral RNA measured by PCR, p24 and p31 viral antigens measured by enzyme-linked immunosorbent assay (ELISA), HIV-1-specific antibody detected by ELISA and HIV-1-specific antibodies detected by western blot, \[[@B16]\]). Patients progress from acute to early chronic infection at the end of stage V, approximately 100 days following infection, as the plasma viral load begins to stabilize.

With respect to the study conducted by clinical data analysis and computer simulation described so far, we identify three regimens, as highlighted in Figure [3](#F3){ref-type="fig"}. These can be paralleled to Fiebig et al. stages \[[@B16]\]. In particular, we observe that patients treated with HAART in very early stages of the infection (stage I-III) are likely to better control the viremia after treatment interruption \[[@B3]\]. If therapy starts in the acute phase (stage V-VI) then the action of the drug foils the immune response and, as a consequence, at the end of the therapeutic period, the virus rebounds undisturbed.

These considerations are summarized in Figure [5](#F5){ref-type="fig"} where we draw a schematic picture of the importance of an early initiation of HAART with respect to the progression of HIV markers according to Fiebig\'s et al. stages. In particular we identified the \"window of opportunity\" corresponding to stages I-III, that is, the first three weeks from primary HIV-1 infection. Patients receiving therapy in this narrow period are likely to turn out to be best controllers. Probably, the massive immune activation in the early stage of the disease favors the virus, as it finds more host target cells to exploit for replication. In point of fact, the ensuing massive depletion of CD4+ T cells in mucosal lymphoid tissues, can result in the disruption of the mucosal barrier in the gut. This barrier prevents the translocation of the intestinal flora from the gut to the systemic immune system restricting it to the lamina propia and the mesenteric lymph nodes \[[@B2]\]. HIV-1 infection is indeed associated with a significant increase of plasma lipopolysaccharide levels that is an indicator of microbial translocation, directly correlated with measures of immune activation.

![**Phase diagram**. Schematic diagram of the importance of an early initiation of HAART with respect to the progression of HIV markers according to the staging in \[[@B16]\].](1471-2334-11-56-5){#F5}

Conclusions
===========

A number of studies indicate that interfering with HIV replication by starting the therapy in the early phases of the infection could have a deep impact on the whole disease course. However, HAART is costly, it is onerous for both patient and health care provider, and often brings adverse effects. Its clinical benefit must therefore be weighed against its burden.

In the present study, we resorted to a computer model to study the dynamics of the plasma viral load after prolonged treatment interruption in two groups of *in silico*patients: those who initiate HAART very early and those who start it lately. We evaluated the model comparing the results to clinical data. We found that an opportunity time-window exists for the initiation of HAART (roughly within three weeks before the establishment of viral reservoirs), in which the therapy can control viral replication, preventing generalized immune activation and extensive CD4+ T cell depletion.

Availability and requirements
=============================

An educational version of the immune system simulator is available on our website:

\- Name: C-ImmSim

\- Home page: <http://www.iac.rm.cnr.it/~filippo/C-ImmSim.html>

\- Operating system(s): Linux, Unix Mac OS X, Windows

\- Programming language: C

\- Licence: C-ImmSim is available under a LICENSE AGREEMENT that needs to be signed: <http://www.iac.rm.cnr.it/~filippo/how-to-get-cimmsim_files/LicenseAgreement.pdf>
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